A Phase 2 BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
Phase of Trial: Phase II
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pazopanib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Proof of concept; Therapeutic Use
- Acronyms BIONIKK
- 12 Sep 2017 Trial design of the study presented at the 42nd European Society for Medical Oncology Congress.
- 25 Jul 2017 Planned primary completion date changed from 1 Mar 2019 to 1 May 2020.
- 25 Jul 2017 Status changed from not yet recruiting to recruiting.